Xeris Biopharma Concludes Phase 2 Study To Treat Hypothyroidism

The growth-oriented biopharmaceutical company Xeris Biopharma Holdings, Inc., dedicated to enhancing patient lives through the development and commercialization of cutting-edge products across a spectrum of therapies, has released the topline...

Tris Pharma Bags US FDA Nod For Clonidine Hydrochloride

The US Food and Drug Administration (FDA) has approved Onyda XR (clonidine hydrochloride), a once-daily extended-release oral suspension with nighttime dosing, for the treatment of attention deficit hyperactivity disorder (ADHD) in pediatric...

Foundation Medicine and PMV Pharma Partner To Develop Companion Diagnostic

Foundation Medication, Inc., a trailblazer in molecular profiling for cancer, and Pharmaceuticals, Inc. reported an alliance to foster EFoundation Medication's tissue-based extensive genomic profiling test, FoundationOne CDx, as a companion...

Anti-diabetic Drugs Contributed To Growth in Pharmaceuticals Market

Anti-diabetic drugs are driving the development in the pharmaceuticals market, posting the most noteworthy worth development of over ₹155 crore among the new brands introduced in the previous year .The respiratory section, which clocked deals of...

Enzene Introduces New Drug Discovery Division

Enzene Biosciences has announced the formation of a new drug discovery branch. This broadens the CDMO's service offerings to the biotech industry and complements its EnzeneXTM-equipped biologics manufacturing location in the United States, which...

Piramal Pharma's Net Profit Leaps by 102% in Q4 to Rs 101 Crore

Piramal Pharma has recorded robust financial growth during the final quarter ended March 2024 and its united net benefit has taken a quantum bounce of 102% to Rs. 101 crore from Rs. 50 crore in the relating time of the year before. Its incomes...

© 2024 India Pharma Outlook. All Rights Reserved.